Skip to content
value.today

GVB Biopharma

🇺🇸 Las Vegas, Nevada, USAManufacturingFounded 2019
Total raised
$13 M
5 rounds on record
Latest round
$1 M
Apr 2022
First round on record
May 2020
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of GVB Biopharma
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2022$1 MNo. 5Under $2 million

GVB Biopharma: Raise no. 5, Apr 2022

Investors in this round

1 investor had bought by the notice of May 19, 2022: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
$50,000
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$100,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Jack Feldman · Executive Officer, Director
  • Phillip Swindells · Executive Officer, Director
  • William Spiegel · Executive Officer, Director
  • Theodore Swindells · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • TerraNova Capital Equities, Inc. (CRD 45097) · New York, New YorkSold in AK, AL, AR, AZ, CA, CO, CT, FL, GA, HI, ID, IL, IN, KS, KY, LA, MA, MI, MN, MO, MS, MT, NC, NH, NJ, NM, NY, OH, OR, PA, SC, TX, UT, VA, VT, WA, WI

Signed by Jonathan Staffeldt, General Counsel. Source: SEC Form D, newest notice filed May 19, 2022. Read the notice at the SEC.

debt, optionsSEC
Jan 2022$2 MNo. 4Under $2 million

GVB Biopharma: Raise no. 4, Jan 2022

Investors in this round

2 investors had bought by the notice of Jan 19, 2022: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
$50,000
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$25,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Jack Feldman · Executive Officer, Director
  • Phillip Swindells · Executive Officer, Director
  • William Spiegel · Executive Officer, Director
  • Theodore Swindells · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • TerraNova Capital Equities, Inc. (CRD 45097) · New York, New YorkSold in AK, AL, AR, AZ, CA, CO, CT, FL, GA, HI, ID, IL, IN, KS, KY, LA, MA, MI, MN, MO, MS, MT, NC, NH, NJ, NM, NY, OH, OR, PA, SC, TX, UT, VA, VT, WA, WI

Signed by Jonathan Staffeldt, Chief Legal Officer. Source: SEC Form D, newest notice filed Jan 19, 2022. Read the notice at the SEC.

debt, optionsSEC
Oct 2021$2 MNo. 3Under $2 million

GVB Biopharma: Raise no. 3, Oct 2021

Investors in this round

10 investors had bought by the notice of Nov 3, 2021: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
$25,000
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$100,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Jack Feldman · Executive Officer, Director
  • Phillip Swindells · Executive Officer, Director
  • William Spiegel · Executive Officer, Director
  • Theodore Swindells · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • TerraNova Capital Equities, Inc. (CRD 45097) · New York, New YorkSold in AK, AL, AR, AZ, CA, CO, CT, FL, GA, HI, ID, IL, IN, KS, KY, LA, MA, MI, MN, MO, MS, MT, NC, NH, NJ, NM, NY, OH, OR, PA, SC, TX, UT, VA, VT, WA, WI

Signed by Jonathan Staffeldt, General Counsel. Source: SEC Form D, newest notice filed Nov 3, 2021. Read the notice at the SEC.

debt, optionsSEC
Nov 2020$8 MNo. 2$2 to $10 million

GVB Biopharma: Raise no. 2, Nov 2020

Investors in this round

28 investors had bought by the notice of Nov 27, 2020: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered; $0 M still to sell
Smallest investment taken
$500,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$640,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Jack Feldman · Executive Officer, Director
  • Phillip Swindells · Executive Officer, Director
  • William Spiegel · Executive Officer, Director
  • Theodore Swindells · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • M.S. Howells & Co. (CRD 104100) · Scottsdale, ArizonaSold in AZ, CA, CT, IN, NY, PA, TX
  • TerraNova Capital Equities, Inc. (CRD 45097) · New York, New YorkSold in AK, AL, AR, AZ, CA, CO, CT, FL, GA, HI, ID, IL, IN, KS, KY, LA, MA, MI, MN, MO, MS, MT, NC, NH, NJ, NM, NY, OH, OR, PA, SC, TX, UT, VA, VT, WA, WI

Signed by Jonathan Staffeldt, General Counsel. Source: SEC Form D, newest notice filed Nov 27, 2020. Read the notice at the SEC.

equity, optionsSEC
May 2020$1 MNo. 1Under $2 million

GVB Biopharma: Raise no. 1, May 2020

Investors in this round

1 investor had bought by the notice of May 27, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $3 M offered; $2 M still to sell
Smallest investment taken
$50,000
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$300,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Nevada

People named in the notice

  • Jack Feldman · Executive Officer, Director
  • Phillip Swindells · Executive Officer, Director
  • William Spiegel · Executive Officer, Director
  • Theodore Swindells · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • TerraNova Capital Equities, Inc. (CRD 45097) · New York, New YorkSold in AK, AL, AR, AZ, CA, CO, CT, FL, GA, HI, ID, IL, IN, KS, KY, LA, MA, MI, MN, MO, MS, MT, NC, NH, NJ, NM, NY, OH, OR, PA, SC, TX, UT, VA, VT, WA, WI

Signed by Jonathan Staffeldt, General Counsel. Source: SEC Form D, newest notice filed May 27, 2020. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • GVB Biopharma chose not to state its revenue in its newest notice of a funding round (May 2022).

    SEC Form D · May 2022

  • The industry group it chose in its notices: Manufacturing.

    SEC Form D · May 2022

That is all the official record says: GVB Biopharma has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of GVB Biopharma is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 28 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by GVB Biopharma
NameRoleNamed in
Jack FeldmanExecutive officerMay 2022
Phillip SwindellsExecutive officerMay 2022
William SpiegelExecutive officerMay 2022
Jack FeldmanDirectorMay 2022
Phillip SwindellsDirectorMay 2022
Theodore SwindellsDirectorMay 2022
William SpiegelDirectorMay 2022